Special Issue "Pharmaceutical Nanotechnology"
A special issue of Nanomaterials (ISSN 2079-4991).
Deadline for manuscript submissions: 30 November 2017
Prof. Dr. Erem Bilensoy
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
Website | E-Mail
Interests: Tumor targeted nanoparticles; Cyclodextrin based nanocarriers (nanoparticles, nanocapsules, nanofibers, hydronanogels); Amphiphilic cyclodextrins ; Cationic nanoparticulate drug delivery systems; Wound healing; Bioavailability enhancement through cyclodextrin complexation; Inkjet and 3D printed drug delivery systems
Pharmaceutical nanotechnologies, over the past twenty years, have shown great potential for drug delivery due to their unique biopharmaceutical properties. The first breakthrough applications were related to the intravenous administration of anticancer drugs, loaded liposomes, opening the possibility to target tumor parenchyma via the enhanced-permeability and retention effect. However, more recently, the development of manufactured nanocarriers, starting from different materials, and with more or less complex surface modifications, has widened the possibilities of drug-loaded nanoparticles, allowing for administration via different administration routes, stimuli or environment responsive drug delivery, active targeting of organs or specific cells and multiple actions, as in the case of theranostics.
This Special Issue of Nanomaterials will attempt to cover recent advances in Pharmaceutical Nanotechnologies for drug delivery, including biodegradable, surface-modified, stimuli-responsive or targeted nanoparticles, liposomes, and micelles designed for parenteral or non-parenteral administration routes.
Prof. Dr. Fabio Sonvico
Prof. Dr. Erem Bilensoy
Prof. Dr. Adriana Raffin Pohlmann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- parenteral administration
- oral delivery
- nasal delivery
- pulmonary delivery
- topical delivery
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Drug delivery system for emodin based on mesoporous silica SBA-15
Authors: Tamara Krajnović, Danijela Maksimović-Ivanić, Sanja Mijatović, Dijana Drača, Katharina Wolf, David Edeler, Ludger A. Wessjohann and Goran N. Kaluđerović*
Abstract: In this study mesoporous silica SBA-15 was evaluated as a vehicle for the transport of the cytotoxic natural product emodin (EO). SBA-15 was loaded with different quantities of EO (SBA-15|EO1-SBA-15|EO5: 8-36 %) and characterized by traditional methods. Several parameters (stabilities) and the in vitro behavior on tumor cell lines (melanoma A375, B16 and B16F10) were investigated. SBA-15 suppresses EO release in acidic milieu, pointing out that EO will not be discharged in the stomach. Furthermore, SBA-15 protects EO from photodecomposition. In vitro studies showed a dose dependent decrease of cellular viability which is directly correlated with an increasing amount of EO in SBA-15 for up to 27 % of EO, while a constant activity for 32 % and 36 % of EO in SBA-15 was observed. Additionally, SBA-15 loaded with EO (SBA-15|EO3) does not disturb viability of peritoneal macrophages. SBA-15|EO3 causes inhibition of tumor cell proliferation and triggers apoptosis, connected with caspase activation, upregulation of Bax, as well as Bcl-2 and Bim downregulation along with amplification of PARP fragmentation. Thus, the mesoporous SBA-15 is a promising carrier of the water-insoluble drug emodin.
Title: Lipid-based nanoparticles as a potential drug delivery approach in the treatment of rheumatoid arthritis
Author: Jia-You Fang
Abstract: Rheumatoid arthritis (RA), a chronic and joint-related autoimmune disease, results in immune dysfunction and destruction of joints and cartilages. Small molecules and biologic therapies have been applied in a wide variety of inflammatory disorders, but theirs utility as a therapeutic agent is limited by its poor absorption, rapid metabolism and serious side effects. To improve these limitations, nanoparticles, as drug delivery systems, are capable of encapsulating and protecting drugs from degradation before to reaching target site in vivo. The present researches purpose a platform for different lipid nanoparticles approaches for RA therapy, taking advantage of the new emerging field of lipid nanoparticles to develop a targeted theranostic system for in vivo administration in RA. This review aims at providing that the recent major applications of lipid nanoparticle, a biocompatible and biodegradable delivery system, effectively improve targeting over free drugs via presentation of tissue-specific targeting ligands and offer controlled drug release by altering nanoparticle composition in RA.
Tentative Title: Cabazitaxel loaded electrospinning nanofibers for in situ glioma therapy
Author: Gang Guo
Affiliation: State Key Laboratory of Biotherapy and Cancer Center, Sichuan University
Abstract: Gliomas are the most common tumors in the central nervous system, of which the prognosis is exactly poor. The efficacy of conventional therapeutic methods including surgical removal, radiation therapy and chemotherapy is weakened due to the recurrence of the tumors. Surgical removal is infeasible because of the tumor size and the tumor location, which leads to high mortality of gliomas. On the contrary, the localized drug delivery is a safer and more efficient strategy due to the sustained drug release and reduced drug toxicity. Cabazitaxel (CBZ), a next-generation taxane for the treatment of hormone-refractory prostate cancer, has been proved that can penetrate blood-brain barrier (BBB) and shows potentials for inhibiting tumors in the central nervous system (CNS). In this study, we prepared CBZ loaded nanofibers consisted of PPC and modified chitosan (CS). Chitosan presents bioactivities of antioxidancy, antimicobes and immunocompetence, but its application is hampered by the poor solubility. PDLLA side chains were grafted to chitosan, which broke the intermolecular bonds hence remarkably improved solubility of CS in common organic solvents. The anti-tumor effects of the nanofibers were evaluated ex vivo and in vivo. Annexin V/PI analysis, immunohistochemistry staining (IHC) and TUNEL results confirmed that the CBZ loaded PPC/GTCS mats inhibited the growth of glioma by inhibiting the proliferation and triggering the apoptosis of tumor cells. The CBZ loaded nanofibers showed great potent for the treatment of glioma.